Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

No New Patients Should Start Treatment with Olaratumab After ANNOUNCE Study Shows It Does Not Prolong Life

It is estimated that around 1,000 patients are currently treated in the EU
24 Jan 2019
Cytotoxic Therapy
Sarcoma

On 23 January 2019, the European Medicines Agency (EMA) issued a press release to announce that preliminary results from the ANNOUNCE study  show that olaratumab (Lartruvo) in combination with doxorubicin is not more effective at prolonging the lives of patients with soft tissue sarcoma than doxorubicin alone. While full results from the study are awaited, EMA is recommending that no new patients should start treatment with the medicine.

For patients currently being treated with Lartruvo, their doctor may consider continuing treatment with the medicine if they appear to benefit from it. It is estimated that around 1,000 patients are currently treated with Lartruvo in the EU.

Based on the information available so far, there are no new safety concerns with the medicine, with side effects reported with the combination being similar to those with doxorubicin alone.

Lartruvo was authorised in November 2016 to treat advanced soft tissue sarcoma, a condition for which there is a lack of suitable medicines. At time of its approval, data on the effects of Lartruvo were limited because of the small number of patients included in the main study which supported authorisation. The medicine was therefore granted a marketing authorisation  on condition that the company provides additional data from the ANNOUNCE study in order to confirm the efficacy and safety of the medicine.

Healthcare professionals will be informed in writing of the preliminary results of the study and the current treatment recommendations. EMA will communicate further as appropriate.

Information for healthcare professionals

  • The phase III study ANNOUNCE evaluated Lartruvo in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma and did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as compared with doxorubicin alone.
  • The study did not meet its primary objective to prolong survival in the overall population (HR: 1.05; median 20.4 vs. 19.7 months for Lartruvo plus doxorubicin and doxorubicin, respectively) or in the leiomyosarcoma sub-population (HR: 0.95; median 21.6 months for Lartruvo plus doxorubicin versus 21.9 months for doxorubicin).
  • Additionally, no benefit was shown in terms of prolonging progression-free survival in the overall population (HR: 1.23; median 5.4 months for Lartruvo plus doxorubicin versus 6.8 months for doxorubicin), which was one of the secondary objectives of the study.
  • As a consequence, no new patients should be prescribed Lartruvo.
  • While further assessment of the study results is ongoing, doctors may consider continuing Lartruvo treatment in patients who experience clinical benefit.
  • No new safety concerns were identified during the study and the safety profile was comparable in the two treatment arms.
  • A letter will be sent to all healthcare professionals expected to prescribe the medicine to inform them of the preliminary results of the study and the current treatment recommendations.

Information for patients

  • A new study showed that Lartruvo in combination with doxorubicin is not more effective at prolonging patients’ lives than doxorubicin alone.
  • No new patients should start treatment with the medicine.
  • If you are being treated with Lartruvo, you should discuss with your doctor whether to continue treatment with the medicine.
  • There are no new safety concerns with the medicine.

More about the medicine

Lartruvo is a cancer medicine that was authorised to treat adults with advanced soft tissue sarcoma, a type of tumour that affects the soft, supportive tissues of the body such as muscles, blood vessels and fat tissue.

Lartruvo is for use together with doxorubicin in patients who cannot undergo surgery or radiotherapy and who have not been previously treated with doxorubicin.

Lartruvo was granted a conditional approval on 9 November 2016. More information about the medicine can be found on the EMA website.

More about conditional approval

Conditional marketing authorisations  are one of the EU’s early access routes for medicines. This tool allows for the early approval of a medicine on the basis of less complete clinical data than is normally required. It applies to medicines that target a seriously debilitating or life-threatening disease or a rare disease, as well as medicines intended for use in emergency situations in response to a public health threat.

While available data may not be comprehensive, they must still demonstrate that the medicine’s benefits outweigh its risks and the applicant should be in a position to provide the comprehensive clinical data after authorisation in a timely manner. These medicines are subject to specific post-authorisation obligations that aim to obtain complete data on the medicine.

Conditional marketing authorisations  are valid for one year. EMA reviews the data available on the medicine yearly and re-assesses the benefit-risk balance. The Agency then issues an opinion on whether the specific obligations  or their timeframes need to be retained or modified and whether the marketing authorisation  should be maintained, varied, suspended or revoked.

Last update: 24 Jan 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.